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Abstract  
 
Background: Medical nutrition therapy is a mainstay of GDM treatment. However, data are 
limited regarding the optimal diet for achieving euglycemia and improved perinatal outcomes. 
Purpose: To investigate whether modified dietary interventions are associated with improved 
glycemia and/or improved birthweight outcomes in women with GDM when compared to 
control dietary interventions.  
Data Sources: Twelve databases.  
Study Selection: Published randomized controlled trials (RCTs) that reported on dietary 
components, maternal glycemia and birthweight. 
Data Extraction: Data were extracted in duplicate using pre-specified forms.  
Data Synthesis: From 2269 records screened, eighteen RCTs involving 1151 women were 
included. Pooled analysis demonstrated that for modified dietary interventions when compared to 
control, there was a larger decrease in fasting and postprandial glucose (-4.07 mg/dL [95% CI -
7.58, -0.57]; p=0.02 and -7.78 mg/dL [95% CI -12.27, -3.29]; p=0.0007 respectively) and a 
lower need for medication treatment (RR 0.65 [95% CI 0.47, 0.88]; p=0.006). For neonatal 
outcomes, analysis of 16 RCTs including 841 participants showed that modified dietary 
interventions were associated with lower infant birthweight (-170.62 g [95% CI -333.64, -7.60]; 
p=0.04) and less macrosomia (RR 0.49 [95% CI 0.27, 0.88]; p=0.02). The quality of evidence for 
these outcomes was low to very low.  
Limitations: Baseline differences between groups in postprandial glucose may have influenced 
glucose-related outcomes. As well, relatively small numbers of study participants limit between-
diet comparison.  
Conclusions: Modified dietary interventions favorably influenced outcomes related to maternal 
glycemia and birthweight. This indicates that there is room for improvement in usual dietary 
advice for women with GDM. 
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Gestational diabetes is one of the most common medical complications in pregnancy and affects 
an estimated 14% of pregnancies, or one in every seven births globally (1). Women with 
gestational diabetes and their offspring are at increased risk of both short and of longer-term 
complications including, for mothers, later development of type 2 diabetes, and for offspring, 
increased lifelong risks of developing obesity, type 2 diabetes, and metabolic syndrome (2-6). 
The adverse intrauterine environment causes epigenetic changes in the fetus that may contribute 
to metabolic disorders, the so-called “vicious cycle” of diabetes (7).  
 
The mainstay of gestational diabetes treatment is dietary and lifestyle advice, which includes 
medical nutrition therapy, weight management and physical activity (8). Women monitor their 
fasting and post-meal glucose levels and adjust their individual diet and lifestyle to meet their 
glycemic targets. This pragmatic approach achieves the glycemic targets in approximately two 
thirds of women with gestational diabetes (8). However, despite the importance of medical 
nutrition therapy and its widespread recommendation in clinical practice, there are limited data 
regarding the optimal diet for achieving maternal euglycemia (8-11). It is also unknown whether 
the dietary interventions for achieving maternal glycemia are also effective for reducing 
excessive fetal growth and adiposity (12).  
 
Different dietary strategies have been reported including low glycemic index, energy restriction, 
increasing or decreasing carbohydrates, or those that modify fat or protein quality or quantity 
(12-14). Three recent systematic reviews have been performed examining specific diets and 
pregnancy outcomes (15-17). Viana et al (16) and Wei et al. (15) concluded that low glycemic 
index diets were associated with a decreased risk of infant macrosomia. However, the most 
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recent systematic review from Cochrane included 19 trials randomizing 1398 women found no 
clear difference in large for gestational age or other primary neonatal outcomes with low 
glycemic index diet (17). The primary maternal outcomes were hypertension (gestational and/or 
preeclampsia), delivery by cesarean section and type 2 diabetes, outcomes for which most trials 
lacked statistical power, even when dietary subgroups were combined. Remarkably, no 
systematic reviews examined the impact of modified dietary interventions on the detailed 
maternal glycemic parameters including change in glucose-related variables, the outcomes which 
are most directly influenced by diet.  
 
To address this knowledge gap, we performed a systematic review and meta-analysis of 
randomized controlled trials to investigate whether in women with gestational diabetes, modified 
dietary interventions (defined as a dietary intervention different from the usual one used in the 
control group) offer improved glycemic control and/or improved neonatal outcomes when 
compared to standard diets.  
 
 
Methods  
In accordance with a published protocol (PROSPERO CRD42016042391), we performed a 
systematic review and meta-analysis. Reporting is in accordance with the Preferred Reporting 
Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. An international panel 
of experts was formed by the International Life Sciences Institute, Europe. This panel 
determined the review protocol and carried out all aspects of the review.  
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Data Sources and Search Strategy  
The following databases were searched for all available dates using the search terms detailed in 
Table S1: PubMed, Medline, Cochrane Central Register of Controlled Trials (CENTRAL), 
Embase, CINAHL, Web of Science Core Collection, Applied Social Sciences Index & Abstracts 
(ASSIA) ProQuest, ProQuest Dissertations & Theses: A&I and UK & Ireland, NICE evidence 
search, Scopus, UK Clinical Trials Gateway, ISRCTN, and ClinicalTrials.gov. The initial search 
was performed in July, 2016. An updated search of Medline, Embase, Cochrane Central Register 
of Controlled Trials and CINAHL was performed on October 3rd, 2017 using the same search 
terms.  
 
A hand-search of relevant reviews and all included articles was conducted to identify studies for 
potential inclusion. As well, experts on the panel were consulted for the inclusion of additional 
articles. Reference management was carried out using EndNote.  
 
Study Selection 
All titles and abstracts were assessed independently and in duplicate to identify articles requiring 
full text review. Published studies fulfilling the following criteria were included: randomized 
controlled trials, evaluated modified dietary interventions on women with gestational diabetes, 
glucose intolerance or hyperglycemia during pregnancy, reported on primary maternal and 
neonatal outcomes, included women aged 18-45 years, had a duration of two weeks or more and 
were published in English, French, Spanish, Portuguese, Italian, Dutch, German or Chinese. We 
excluded studies which included participants with type 1 or type 2 diabetes if data for 
participants with gestational diabetes were not presented independently, if dietary characteristics 
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were not available, if the study was in animals, or did not report outcomes of interest. We did not 
include studies of nutritional supplements such as vitamin D or probiotics as recent reviews have 
addressed these topics (18; 19).  
 
All citations identified after title and abstract assessment were full text reviewed in duplicate. 
Reasons for exclusion at the full text review stage were recorded. Any disagreements between 
reviewers were resolved by consensus and with consultation with the expert group when 
required.  
 
Data Extraction  
Data from included studies were extracted in duplicate using pre-specified data extraction forms. 
Extracted data elements included study and participant demographics, study design, diagnostic 
criteria for gestational diabetes, glucose intolerance or hyperglycemia, funding source, 
description of modified dietary intervention and comparator, maternal and neonatal outcomes. 
For studies with missing data, inconsistencies or other queries, authors were contacted. Record 
management was carried out using Microsoft Excel and RevMan.   
 
For articles providing information on maternal weight, fasting glucose, postprandial glucose, 
HbA1c or HOMA-IR at baseline and post-intervention but not their change, change was 
calculated as the difference between post-intervention and baseline. Standard deviations were 
imputed using the correlation coefficient observed in articles reporting full information on the 
variable at baseline, post-intervention and its change or a correlation coefficient of 0.5 when this 
information was not available (11). As studies differed in postprandial glucose at baseline, 
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glycemic control at study entry was not considered to be equivalent in both arms and thus 
continuous glucose-related variables at follow-up are reported as change from baseline. 
 
Data Synthesis 
The primary outcomes were maternal glycemic outcomes (mean glucose, fasting glucose, 
postprandial glucose [post-breakfast, lunch, dinner and combined], hemoglobin A1c [HbA1c], 
assessment of insulin sensitivity by homeostasis model assessment of insulin resistance index 
[HOMA-IR], and change in these parameters from baseline to assessment; medication treatment 
[defined as oral diabetes medications or insulin]), and neonatal birthweight outcomes 
(birthweight, macrosomia, and large for gestational age).  
 
Data were pooled into relative risks or mean differences with 95% confidence intervals (95% CI) 
for dichotomous outcomes and continuous outcomes respectively. Meta-analysis was performed 
using random effect models. A pre-specified analysis stratified by type of diet and quality 
assessment was performed to explore potential reasons for inter-study variation. Heterogeneity 
was assessed using I2 statistics. Small study effects were examined for using funnel plots. 
Analyses were conducted using RevMan version 5.3. Pooled estimation of birthweight in the 
study and control arms, both overall and according to the specific diet intervention was 
performed using Stata 14.0. 
 
Quality Assessment 
Methodological quality and bias assessment was completed by two reviewers. Risk of bias was 
assessed using the Cochrane Collaboration tool, which rates seven items as being high, low or 
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unclear risk of bias (20). These items included random sequence generation, allocation 
concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete 
outcome data, selective outcome reporting and other potential sources of bias (20). A sensitivity 
analysis was performed excluding articles with relevant weaknesses in trial design or execution. 
 
The overall quality of the evidence was also assessed using Grading of Recommendations, 
Assessment, Development and Evaluation (GRADE) working group guidelines (11). GRADE 
was assessed for all primary and secondary, both maternal and neonatal, but without subgroup 
analysis per different dietary intervention for each outcome measure. 
 
Results 
We screened 2269 records for potential inclusion and 126 articles were reviewed in full (Figure 
S1). Eighteen studies (12-14; 21-35) were included in the meta-analysis with a total of 1151 
pregnant women with gestational diabetes.  
 
Study Characteristics  
The types of modified dietary intervention included low glycemic index (n=4), DASH (n=3), low 
carbohydrate (n=3), fat modification (n=2), soy protein enrichment (n=2), energy restriction 
(n=1), high fiber (n=1), ethnic diet (i.e. foods commonly consumed according to participant’s 
ethnicity) (n=1) and behavioral intervention (n=1). Details of the study characteristics are 
included in Table 1. Most trials were single centered and had small sample sizes (range 12-150). 
Only two trials (one each from Spain and Australia) included over 100 participants, nine had 50-
100 participants and seven studies had fewer than 50 participants. They were performed in North 
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America, Europe, or Australasia and all had a duration of at least two weeks. The ethnicity of 
participants was reported in seven studies (12; 13; 25; 28; 30; 31; 33).  
 
Most studies assessed individual dietary adherence using food diaries (13; 22-36). While most 
studies did report an overall difference in dietary composition between the intervention diet and 
control diet, few studies reported a detailed assessment of dietary adherence. Only five studies 
used of a formal measure of adherence (23; 24; 28; 32; 33) and four of them reported data (24; 
28; 32; 33). Adherence ranged from 20 to 76% in the control group and 60 to 80% in the 
intervention groups. 
 
 
Participant Characteristics 
When baseline characteristic data were pooled, women in the intervention group were older than 
women in the control group (pooled mean difference 0.60 years [95% CI 0.06, 1.14]) and had 
higher postprandial glucose (pooled mean difference 5.47 [95% CI 0.86, 10.08]) most influenced 
by the DASH and ethnic studies. There was no overall significant difference between the 
intervention and control groups for body mass index (BMI), gestational age at enrolment, fasting 
glucose, HbA1c, or HOMA-IR.  
 
Maternal Glycemic Outcomes for all Modified Dietary Interventions 
Pooled risk-ratios in 15 studies involving 1023 women demonstrated a lower need for 
medication (RR 0.65 [95% CI 0.47, 0.88; I2=55]) (Table 2). Thirteen studies (n= 662 women) 
reported fasting glucose levels, nine (n=475) reported combined post-prandial glucose measures 
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and three (n=175) reported post-breakfast glucose measures. Pooled analysis demonstrated a 
larger decrease in fasting, combined postprandial and post-breakfast glucose levels in modified 
dietary interventions (-4.07 mg/dL [95% CI -7.58, -0.57; I2=86; p=0.02], -7.78 mg/dL [95% CI -
12.27, -3.29; I2=63; p=0.0007] and -4.76 mg/dl [95% CI -9.13, -0.38]; I2=34; p=0.03] 
respectively) compared to control group. There were no significant differences in change in 
HbA1c (7 studies), HOMA-IR (4 studies), or in post-lunch or -dinner glucose levels (2 studies).  
 
Neonatal Birthweight Outcomes for All Diets  
Pooled mean birthweight was 3266.65g (95% CI 3172.15, 3361.16) in the modified dietary 
intervention versus 3449.88 g (95% CI 3304.34, 3595.42) in the control group. Pooled analysis 
of all 16 modified dietary interventions including 841 participants demonstrated lower 
birthweight (-170.62 g [95% CI -333.64, -7.60; I2=88]; p=0.04) and less macrosomia (RR 0.49 
[95% CI 0.27,0.88; I2=11]; p=0.02) compared to conventional dietary advice (Table 2 and Figure 
1). There was no significant difference in the risk of large for gestational age newborns in 
modified dietary interventions as compared to control diets (RR 0.96 [95% CI 0.63,1.46; I2=0]; 
p=0.85). 
 
Subgroup Meta-Analysis by Types of Dietary Interventions 
Pooled analysis of low glycemic index diets showed a larger decrease in fasting glucose (25; 29; 
37), postprandial and post-breakfast glucose compared to control diets (25; 29) (Table 2). 
Whereas pooled analysis of the DASH diet, showed significant favorable modifications in 
several outcomes, including change in fasting (21; 35) and postprandial glucose (21), HOMA-IR 
(35), HbA1c (21) medication need (21; 22; 35), infant birthweight (22; 35) and macrosomia (22; 
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35) (Table 2 and 3). Lastly, pooled analysis of soya protein-enriched diet demonstrated a 
significant decrease in medication use and birthweight (14; 26) (Table 2 and 3). One soya protein 
intervention (n=68 participants) described significantly lower HOMA-IR (35) (Table 2).  
 
One study for each of behavioral and ethnic specific modified dietary interventions was included.  
The behavioral change dietary intervention reported significant differences in change in 
postprandial glucose, and in HbA1c (Table 2) (23). Ethnic diet demonstrated a significantly 
larger decrease in fasting and in postprandial glucose (Table 2) (33). Fat modification, low 
carbohydrate, and energy restriction diets were not associated with a significant difference in our 
primary outcomes in the stratified analysis.  
 
Secondary Outcomes  
Weight gain from inclusion was lower for low carbohydrate diets and cesarean birth for DASH 
diets (Table S2). Specific diet interventions did not show significant between-group differences 
in maternal gestational weight gain throughout pregnancy, preeclampsia/eclampsia, neonatal 
hypoglycemia as defined by the authors, preterm birth, neonatal intensive care unit admission or 
small for gestational age newborns (Table S2 and S3).  
 
Sensitivity Analysis of Primary Outcomes 
Sensitivity analysis was performed to explore reasons for heterogeneity and to assess outcomes 
when studies with methodological concerns were removed. We were unable to include four 
studies (21; 22; 33; 35), including all the DASH diet studies where clarification of certain aspects 
of the results could not be obtained, even after a direct approach to the authors. The authors of 
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the ethnic diet study authors responded to queries but did not provide the required information 
regarding gestational age at randomization (33). After these studies are removed, the changes in 
postprandial (-5.90 mg/dL [95% CI -7.93, -3.88]; I2=0; p=0.0001), and in post-breakfast glucose 
levels (-4.76 mg/dl [95% CI -9.13, -0.38]; I2=34; p=0.03) and birthweight (-74.88 g [95% CI -
144.86, -4.90]; I2=1; p=0.04) remained significant when all diets were combined (Tables 3). 
Furthermore, the heterogeneity in most primary outcomes decreased after removal of these four 
studies. 
 
When dietary subgroups were assessed, low glycemic index diets had significant differences in 
changes in fasting (-5.33 mg/dl [95% CI -6.91, -3.76]) (25; 28; 29), postprandial (-7.08 mg/dl  
[95% CI -12.07, -2.08]) (25; 29) and post-breakfast glucose (-8.6 mg/dl  [95% CI -14.11, -3.09]) 
(25; 29). The soya protein diet had differences in change of HOMA-IR (-2.00 [95% CI -3.17, -
0.83]) (26), required less medication use (RR 0.44 [95% CI 0.21, 0.91]) and had a lower 
birthweight (-184.67 g [95% CI -319.35, -49.98]) (14; 26). The behavior modification diet had 
significant differences in change in postprandial glucose (-6.90 mg/dl [95% CI -9.35, -3.95]) and 
in HbA1c (-0.19 % [95%CI -0.26, -0.12]) (23).  
 
Assessment of Bias and Quality of the Evidence  
None of the included studies were assessed as having a low risk of bias in all seven items of the 
Cochrane Collaboration Tool (Figure S2). Most studies were high risk for blinding of 
participants and personal and for other sources of bias (Figure S3). Studies scored high risk for 
other sources of bias for concerns such as baseline differences and industry funding. Most 
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studies had an “unclear risk of bias” for selective outcome reporting and very few had registered 
protocols (Figure S3).  
 
GRADE assessment for the outcomes of interest reveals overall low to very low quality of 
evidence (Table S4). Considerations to downgrade quality of evidence involved the entire 
spectrum, including limitations in the study design, inconsistency in study results, indirectness 
and imprecision in effect estimates.  
 
Evaluation for Small Study Effect  
Funnel plots of means and relative risks of the primary outcomes for the main analysis are shown 
in Figures S4 and S5 and for the sensitivity analysis in Figures S6 and S7. Overall, funnel plot 
asymmetry improves with the sensitivity analysis compared to the main analysis for neonatal 
birthweight outcomes.   
 
Discussion  
In this meta-analysis, we pooled results from 18 studies including 1151 women with a variety of 
modified dietary interventions. Remarkably, this is the first meta-analysis with a comprehensive 
analysis on maternal glucose parameters. Despite the heterogeneity between studies, we found a 
moderate effect of dietary interventions on maternal glycemic outcomes including changes in 
fasting, post-breakfast and postprandial glucose levels, need for medication treatment and on 
neonatal birthweight. After removal of four studies with methodologic concerns, we saw an 
attenuation of the treatment effect. Nonetheless, the change in post-breakfast and postprandial 
glucose levels as well as lowering of infant birthweight remained significant. Given the 
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inconsistencies between the main and sensitivity analysis, we consider that conclusions should 
be drawn after the last one. These data suggest that dietary interventions modified above and 
beyond usual dietary advice for gestational diabetes have potential to offer better maternal 
glycemic control and infant birthweight outcomes. However, the quality of evidence, was judged 
as low to very low due to the limitations in the design of included studies, the inconsistency 
between their results and the imprecision in their effect estimates. 
 
Previous systematic reviews have focused on the easier to quantify outcomes like the decision to 
start additional pharmacotherapy, glucose-related variables at follow-up not addressing change 
from baseline, birthweight, and pregnancy outcome (16-18). The most recently published 
Cochrane systematic review by Han et al. did not find any clear evidence of benefit other than a 
possible reduction in caesarean section associated with DASH diet (17). The very high 
carbohydrate intake (~400g/day), and 12 servings of fruit and vegetables in the DASH diet (23; 
24), limit its clinical applicability and generalizability to women from lower socio-economic, 
inner city backgrounds in western countries. The Cochrane review shared one of our primary 
outcomes, large for gestational age (17). Neither meta-analysis detected a significant difference 
in risk of large for gestational age because the trials with a larger effect on birthweight (the three 
DASH studies) did not report on large for gestational age. 
 
Our findings regarding pooled analysis of low glycemic index dietary interventions are broadly 
consistent with those of Viana et al (16) and Wei et al. (15). Viana et al. noted decreased 
birthweight and insulin use based on four studies of low glycemic index diet among 257 women 
(mean difference -161.9g [95% CI -246.4, -77.4] and RR 0.767 [95% CI 0.597, 0.986], 
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respectively) (16). Wei et al. also reported decreased risk of macrosomia with a low glycemic 
index diet in five studies of 302 women (RR 0.27 [95% CI 0.10, 0.71]) (18). In our analyses of 
four studies in a comparable number of participants (n= 276), we found the same direction of 
these effect estimates, without significant between-group differences. This is most likely due to 
the different studies included. For example, we were unable to obtain effect estimates stratified 
by type of diabetes in the study by Perichart-Perera et al. (which included women with type 2 
diabetes) and therefore did not include this study (40). An important difference between our 
analyses and that of Wei et al. is that they included DASH diet as a low glycemic index dietary 
subtype (18). We also included a recent study by Ma et al. not included by the previous reviews 
(31).  
 
Our sensitivity analyses highlighted concerns regarding some studies included in previous 
reviews. Notably, after removal of the studies with the most substantial methodologic concerns 
in the sensitivity analysis, differences in the change in fasting plasma glucose were no longer 
significant. While differences in the change in postprandial glucose and birthweight persisted, 
they were attenuated.  
 
This review highlights limitations of the current literature examining dietary interventions in 
gestational diabetes. Most studies are too small to demonstrate significant differences in our 
primary outcomes. Seven studies had fewer than 50 participants and only two had more than 100 
participants (n=125 and 150 respectively). The short duration of many dietary interventions, and 
the late gestational age at which they were started (38) may also have limited their impact on 
glycemic and birthweight outcomes. Furthermore, we cannot conclude if the improvements in 
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maternal glycemia and infant birthweight are due to reduced energy intake, improved nutrient 
quality or specific changes in types of carbohydrate and/or protein. 
 
We have not addressed the indirect modifications of nutrients. For example, reducing intake of 
dietary carbohydrates to decrease postprandial glucose may be compensated by a higher 
consumption of fat potentially leading to adverse effects on maternal insulin resistance and fetal 
body composition.  Beneficial or adverse effects of other nutrients such as n-3 LCPUFA, vitamin 
D, iron, and selenium cannot be ruled out.  
 
Our study has important strengths and weakness. To our knowledge, ours is the first systematic 
review of dietary interventions in gestational diabetes comprehensively examining the impact of 
diet on maternal glycemic outcomes assessing the change in fasting, postprandial glucose, 
HbA1c and HOMA-IR from baseline. This is especially important taking into account that 
groups were not well-balanced at baseline. Our review also benefits from the rigorous 
methodology used as well as the scientific, nutritional and clinical expertise from an international 
interdisciplinary panel. However, it also has limitations. Baseline differences between groups in 
postprandial glucose may have influenced glucose-related outcomes. Furthermore, three of the 
included trials were pilot studies and therefore not designed to find between group differences 
(12; 25; 33). The low number of studies reporting on adherence clearly illustrates that the quality 
of the evidence is far from ideal. The heterogeneity of the dietary interventions even within a 
specific type (varied macronutrient ratios, unknown micronutrient intake, short length of some 
dietary interventions) as well as baseline characteristics of women included (such as 
prepregnancy body mass index, or ethnicity) may have also affected our pooled results. It should 
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also be noted that the relatively small numbers of study participants limit between-diet 
comparisons. Lastly, we were unable to resolve queries regarding potential concerns for sources 
of bias because of lack of author response to our queries. We have addressed this by excluding 
these studies in the sensitivity analysis.  
 
Conclusions  
Modified dietary interventions favorably influenced outcomes related to maternal glycemia and 
birthweight. This indicates that there is room for improvement in usual dietary advice for women 
with gestational diabetes. Although the quality of the evidence in the scientific literature is low, 
our review highlights the key role of nutrition in the management of gestational diabetes and the 
potential for improvement if better recommendations based on adequately powered high-quality 
studies were developed. Taking into account the prevalence of gestational diabetes, new studies 
designed to evaluate potential dietary interventions for these women should be based in larger 
study groups with appropriate statistical power. As most women with gestational diabetes are 
entering pregnancy with a high BMI, evidence-based recommendations regarding both dietary 
components and total energy intake are particularly important for overweight and obese women. 
The evaluation of nutrient quality, in addition to their quantity, as well as dietary patterns such as 
Mediterranean diet (39) would also be relevant. In particular, there is an urgent need for well-
designed dietary intervention studies in the low and middle-income countries where the global 
health consequences of gestational diabetes are greatest. 
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Figure Legends  
 
Figure 1: Forest plot of birthweight for modified dietary interventions compared to control 
diets in women with gestational diabetes  
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Table 1: Characteristics of studies included  
 
Author, 
year 
Country n Estimated 
sample size  
Definition of 
Gestational 
Diabetes 
Duration of 
dietary 
intervention  
Gestational age 
in weeks at 
enrollment 
(mean±SD) 
Baseline Body Mass 
Index in kg/m2 
(mean±SD) 
Mean Maternal 
Age in years 
(mean±SD) 
Dietary Intervention Diet Composition* 
Low Glycemic Index (GI) Diet 
Grant, 2011 
(25) 
Canada 47  50 to detect a 
0.6 mmol/L 
difference in 
capillary 
glucose; n not 
achieved  
Canadian 
Diabetes 
Association, 
2008 (40) 
28 weeks until 
delivery  
Control: 29±2.35 
Intervention†: 
29±3.21 
Control: 26±4.69 
Intervention: 
27±4.58 (Pre-
pregnancy) 
Control: 34±0.46 
Intervention: 
34±5.16 
Low GI: Women 
were provided with a 
list of starch choices 
specific to either 
intervention (low GI) 
or control  
Control: GI: 
125.0±0.8.8 
Intervention: GI: 
49.0±0.8 
Louie, 2011 
(28) 
Australia 99  120 to detect 
a 260g 
difference in 
birth weight 
(stopped early 
because of 
smaller than 
expected SD) 
Australasian 
Diabetes in 
Pregnancy 
Society 
criteria (41) 
Randomization 
until delivery  
Control: 
29.7±3.5 
Intervention: 
29±4.0 
Control: 24.1±5.7 
Intervention: 
23.9±4.4 (Pre-
pregnancy) 
Control: 32.4±4.5 
Intervention: 
34±4.1 
Low GI: Target GI 
≤50 but otherwise 
similar composition 
to the control diet  
Control: Energy 
1934±465; Carb 
40.3±8.3; Protein 
22.2±7.5; Fat 
35.1±16.9; GI 
105.0±25.92 
Intervention: Energy 
1836±403; Carb 
38.7±8.3; Protein 
23.4±5.8; Fat 
34.9±11.0; GI 
47.0±6.5 
Ma, 2015 
(29) 
China  95 Not reported  Chinese 
Medical 
Association 
and American 
Diabetes 
Association 
(42) 
24-26 weeks until 
delivery  
Control: 
27.9±1.1 
Intervention: 
27.5±1.1 
Control: 21.15±2.75 
Intervention: 21.90 ± 
3.14 (Pre-pregnancy) 
Control: 30.0±3.5 
Intervention: 
30.1±3.8 
Low GI: Women 
provided with an 
exchange list for 
starch choices 
specific to either 
intervention (low GI) 
or control 
Control: Energy 
2030±215; Carb 
49.8±6.8; Protein 
18.8±2.5; Fat 
31.8±3.8;GI 
135.9±19.0 
Intervention: Energy 
2006±215; Carb 
48.56±7.; Protein 
18.9±2.9; Fat 
32.1±4.1; GI 
50.1±2.2 
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Moses, 
2009 (13) 
Australia 63 Not reported Australasian 
Diabetes in 
Pregnancy 
Society (41) 
28-32 weeks until 
delivery  
Control: 
29.9±1.11 
Intervention: 
30.3±1.11 
Control: 32.8±7.92 
Intervention: 
32.0±6.68 (At 
enrolment)  
Control: 31.3±4.52 
Intervention: 
30.8±3.90 
Low GI: Women 
asked to avoid 
specific high GI 
foods and were 
provided with a 
booklet outlining 
carb choices 
Control: Energy 
1656±433; Carb 
36.2±8.2; Protein 
24.0±4.4; Fat 
34.3±9.9 
Intervention: Energy 
1713±368; Carb 
36.7±6.1; Protein 
23.9±3.9; Fat 
33.4±6.12; GI 
48.0±5.0 
DASH (Dietary Approaches to Stop Hypertension) Diet 
Asemi, 
2013 (21) 
Iran  34 32 for “key 
variable 
serum HDL” 
50g glucose 
challenge 
>140 mg/dl 
 100g 
OGTT; GDM 
if 2+ fasting 
>95 mg/dl, 1 
hr 180 mg/dl, 
2 hr 155 
mg/dl, 3hr 
140 mg/dl 
4 weeks  Not reported Control: 31.4±5.7 
Intervention: 
29.0±3.2 (At 
enrolment)  
Control: 29.4±6.2 
Intervention:  
30.7±6.7 
DASH diet: diet rich 
in in fruit, vegetables, 
whole grains and 
low-fat dairy; low in 
saturated fats, 
cholesterol, refined 
grains and sweets 
Control: Energy 
2392±161; Carb 
54.0±6.9; Protein 
17.6±2.8; Fat 
29.3±5.6 
Intervention: Energy 
2400±25; Carb 
66.8±2.2; Protein 
16.8±1.2; Fat 
17.6±0.9 
Asemi, 
2014 (22) 
Iran  52 42 to detect a 
75g difference 
in birth 
weight  
As above   4 weeks  Control: 
25.9±1.4 
Intervention: 
25.8±1.4 
Control: 31±4.9 
Intervention: 
29.2±3.5 (At 
enrolment) 
Control: 30.7±6.3 
Intervention: 
31.9±6.1 
DASH diet (same as 
above)  
Control: Energy 
2352±163; Carb 
54.2±37.1; Protein 
18.2±3.4; Fat 
28.5±5.6 
Intervention: Energy 
2407±30; Carb 
66.4±2.04; Protein 
17.0±1.3; Fat 
17.4±1.0 
Yao, 2015 
(35) 
China  33 42 to detect a 
75g difference 
in birth 
weight; not 
achieved  
50g glucose 
challenge  
100g OGTT 
results with 2+ 
of: fasting 
>95 mg/dL, 1-
hour ≥180 
4 weeks  Control: 
25.7±1.3 
Intervention: 
26.9±1.4 
Control: 30.9±3.6 
Intervention: 
30.2±4.1 (At 
enrolment)  
Control: 28.3±5.1 
Intervention: 
30.7±5.6 
DASH diet (same as 
above) 
Control: Energy 
2386±174; Carb 
52.3±7.2; Protein 
18.0±3.3; Fat 
28.3±5.1 
Intervention: Energy 
2408±54; Carb 
28 
 
mg/dL, 2-hour 
≥155 mg/dL 
and 3-hour 
≥140 mg/dL 
66.7±2.3; Protein 
16.9±1.2; Fat 
17.17±1.16   
Low Carbohydrate Diets 
Cypryk, 
2007 (24) 
Poland  30 Not reported  WHO criteria  2 weeks  29.2±5.4  Not reported 28.7±3.7  Low (intervention) vs 
high carb (45% vs 
60% of total energy, 
respectively) 
‡Control: Carb 60%; 
Protein 25%; Fat 
15% ‡Intervention: 
Carb 45%; Protein 
25%; Fat 30% 
Hernández, 
2016 (12) 
USA 12 Pilot study to 
estimate SD  
Carpenter and 
Coustan 
Criteria (43) 
30-31 weeks until 
delivery  
Control§: 
31.7±2.45 
Intervention: 
31.2±0.98 
Control: 34.3±3.92 
Intervention: 
33.4±3.43 (At 
enrolment)   
Control: 30±2.45 
Intervention: 
28±4.90 
Low carb 
(intervention) vs 
higher-complex 
carbohydrate/ lower 
fat 
‡Control: Carb 60%; 
Protein 15%; Fat 
25% ‡Intervention: 
Carb 40%; Protein 
15%; Fat 45%  
Moreno-
Castilla, 
2013 (30) 
Spain  152 152 to detect 
a 22% 
difference in 
need for 
insulin  
2006 National 
Diabetes and 
Pregnancy 
Clinical 
Guidelines 
(44; 45) 
 ≤35 weeks until 
delivery 
Control: 
30.1±3.5 
Intervention: 
30.4±3.0 
Control: 26.6±5.5 
Intervention: 
25.4±5.7 (Pre-
pregnancy)  
Control: 32.1±4.4 
Intervention: 
30.4±3.0 
Low carbohydrate 
(intervention) vs 
control (40% vs 55% 
of total diet energy as 
carbohydrate)  
‡Control: Energy 
1800 minimum; Carb 
55%; Protein 20%; 
Fat 25% 
‡Intervention: 
Energy 1800 
minimum; Carb 40%; 
Protein 20%; Fat 
40%  
Soy Protein Enrichment Diets  
Jamilian, 
2015 (26) 
Iran  68 56 (minimum 
clinical 
difference not 
reported)  
One-step 75g 
OGTT, 
American 
Diabetes 
Association 
(46) 
6 weeks  Not reported Control: 28.4±3.4 
Intervention: 
28.9±5.0 
Control: 29.3±4.2 
Intervention: 
28.2±4.6 
Soya protein diet had 
the same amount of 
protein as control diet 
but the protein 
portion was made up 
of 35% animal 
protein, 35% soy 
protein, 30% other 
plant proteins 
Control: Energy 
2426±191; Carb 
54.6±7.1; Protein 
14.4±1.7; Fat 
32.1±5.4 
Intervention: Energy 
2308±194; Carb 
54.6±7.3; Protein 
15.0±2.6; Fat 
30.3±4.7 
Sarathi, 
2016 (14) 
India  62  Not reported  IADPSG 
criteria (47) 
From diagnosis 
until delivery  
Control: 
25.56±1.69 
Intervention: 
25.19±1.92 
Not reported  Control: 
29.17±3.38 
Intervention: 
29.43±2.98 
Soya based protein 
diet: 25% of cereal 
part of high fiber 
complex 
‡Control: Energy 
1600-2000; minimum 
carb 175g; 
‡Intervention: 
29 
 
carbohydrates 
replaced with soya 
Energy 1600-2000; 
minimum carb 175g;  
Fat Modification Diets 
Lauszus, 
2001 (27) 
Denmark  27  20 to detect a 
difference in 
cholesterol of 
0.65 mmol/l  
3-h 75 grams 
OGTT, GDM 
if 2+ glucose 
> 3 SD above 
the mean  
34 weeks until 
delivery  
Not reported Control: 32.2±5.61 
Intervention: 
35.3±8.65 (At 
enrolment)   
Control: 29±3.74 
Intervention: 
31±3.61   
High MUFA 
(monounsaturated 
fatty acids): source 
was hybrid sunflower 
oil with high content 
oleic acid and snacks 
of almonds and 
hazelnuts 
Control: Energy 
1727; Carb 50.0±3.6; 
Protein 19.0±3.6; Fat 
30.0±7.2 
Intervention: Energy 
1982; Carb 46±3.5; 
Protein 16±3.5; Fat 
37±3.5 
Wang, 2015 
(34) 
China  84 Not reported  IADPSG 
criteria (47) 
~27 weeks until 
delivery  
Control: 
27.3±1.96 
Intervention: 
27.4±1.52 
Control: 22.2±3.6 
Intervention: 
21.4±3.0 (Pre-
pregnancy) 
Control: 29.7±4.64 
Intervention: 
30.3±4.17 
Polyunsaturated fatty 
acid meals (50-54% 
carbohydrate, 31-
35% fat with 45-40g 
sunflower oil)  
Control: Energy 
1978±107; Carb 
55.4±2.0; Protein 
17.9±1.0; Fat 
26.7±1.3 
Intervention: Energy 
1960±90; Carb 
47.7±0.7; Protein 
18.0±0.7; Fat 
34.3±0.2 
Other Diets 
Bo, 2014 
(23) 
Italy  99 in diet 
study) 
(total 
n=200)  
200 to detect 
a 10% 
difference in 
fasting 
glucose 
(based on 
exercise 
portion of 
trial)  
75g OGTT 24-26 weeks until 
delivery  
Not reported Control: 26.8±4.1 
Intervention: 
26.9±4.6 
Control: 33.9±5.3 
Intervention: 
35.1±4.4 
Behavioral dietary 
recommendations: 
individual 
recommendations for 
helping dietary 
choices  
Control: Energy 
2116±383; Carb 
46.9±5.9; Protein 
15.6±2.6; Fat 
37.4±4.2 
Intervention: Energy 
2156±286; Carb 
47.8±4.9; Protein 
15.5±2.4; Fat 
36.7±3.9 
Rae, 2000 
(31) 
Australia  124 120 to detect 
a decrease in 
insulin use 
from 40 to 
15% and a 
decrease in 
macrosomia 
from 25 to 5% 
OGTT fasting 
glucose 
>5.4mmol/L 
and/or 2 hour 
glucose 
>7.9mmol/L 
(48) 
<36 weeks until 
delivery  
Control: 
28.3±4.6 
Intervention: 
28.1±5.8 
Control: 38.0±0.7 
Intervention: 
37.9±0.7 (At 
diagnosis)  
Control: 30.6 
Intervention: 30.2 
(SD not reported) 
Moderate energy 
restriction (1590-
1776kcal/day) vs 
control (2010-
2220kcal/day) 
Control: Energy 
1630±339; Carb 
41.0±5.6; Protein 
24.0±2.3; Fat 
34.0±5.3 
Intervention: Energy 
1566±289; Carb 
42.0±5.7; Protein 
30 
 
25.0±2.4; Fat 
31.0±5.7 
Reece, 1995 
(32) 
USA  50 Post-hoc 
calculation  
Not reported  24-29 weeks until 
delivery 
Not reported  Not reported  Not reported  Fiber-enriched diet: 
Fiber taken as fiber-
rich foods (40g/day) 
and a high fiber drink 
(40g/day)  
‡Control: Carb 50%; 
Fat 30%; Fiber 20g/d 
‡Intervention: Carb 
60%; Fat 20% with 
80g fiber/day 
Valentini, 
2012 (33) 
Italy  20 Not reported 
(pilot study)  
4th 
International 
Workshop 
Conference 
on GDM (49) 
From diagnosis 
(screening at 24-
28 weeks) until 
delivery  
Control 27.1±5.9 
Intervention: 
21.3±6.8 
Control: 24.1±4.7 
Intervention: 
25.7±3.6 (Pre-
pregnancy)  
Control: 30.2±4.7 
Intervention: 
28.9±3.3 
Ethnic meal plan: 
foods commonly 
consumed per 
participant’s ethnicity 
with the same kcal 
and nutrient 
composition as the 
control diet 
‡Control: Carb 55%; 
Protein 17%; Fat 
28%; fiber 21g 
‡Intervention: Carb 
55%; Protein 17%; 
Fat 28%; fiber 21g 
* Reported actual dietary intake. When not reported, prescribed dietary intake is reported.; † Intervention is defined as dietary intervention different from the usual dietary intervention used in the control group; ‡ Indicates 
prescribed diet; § The control and intervention groups were reversed for the purpose of meta-analysis so it could be included in the low carbohydrate group. 
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Table 2: Pooled analyses of primary maternal glycemic and infant birthweight outcomes  
 
Outcome  Diet Subgroup No. of 
Studies 
No. of 
Women 
Effect estimate I2 
(%) 
Maternal Glycemic Outcomes  
    Mean [95% CI]  
Change in fasting 
glucose (mg/dl) 
All diets  
13 662 -4.07 [-7.58, -0.57] 
86 
 Low GI (25; 28; 
29) 3 195 -5.28[-6.83, -3.73] 
0 
 
DASH (21; 35) 2 67 
-11.55 [-14.00, -
9.09] 
0 
 Low 
carbohydrate 
(12; 24) 2 42 3.81 [-4.29, 11.92] 
69 
 Fat modification 
(27; 34) 2 109 4.87 [-0.44, 10.18] 
0 
 Soya protein 
(14; 26) 2 130 -7.47 [-20.28, 5.34] 
91 
 Behavior (23) 1 99 -1.50 [-5.66, 2.66] - 
 
Ethnic (33) 1 20 
-25.34 (-37.57, -
13.11) 
- 
Change in postprandial 
glucose (mg/dl) All diets 9 475 
-7.78 [-12.27, -
3.29] 63 
 
Low GI (25; 29) 2 121 
-7.08 [-12.07, -
2.08] 
4 
 
DASH (21) 1 34 
-45.22 [-68.97, -
21.47] 
- 
 Low 
carbohydrate 
(24) 1 30 -3.00 [-10.06, 4.06] 
- 
 Fat modification 
(27; 34) 2 109 -6.43 [-13.08, 0.22] 
0 
 Soya protein 
(14) 1 62 -1.05 [-11.03, 8.93] 
- 
 
Behavior (23) 1 99 
-6.90 [-11.68, -
2.12] 
- 
 
Ethnic (33) 1 20 
-16.28 [-22.83, -
9.73] 
- 
Change in post-breakfast 
glucose (mg/dl) All 3 175 -4.76 [-9.13, -0.38] 34 
 Low GI (29) 1 83 -8.6 [-14.11, -3.09]  - 
 Low 
carbohydrate 
(24) 1 30 -3.00 [-8.15, 2.15] 
- 
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 Soya protein 
(14) 1 62 -1.05 [-9.73, 7.63] 
- 
Change in post-lunch 
glucose (mg/dl)  All 2 92 4.50 [-1.90, 10.90] 0 
 Low 
carbohydrate 
(24) 1 30 4.00 [-4.56, 12.56] 
- 
 Soya protein 
(14) 1 62 5.14 [-4.51, 14.79] 
- 
Change in post-dinner 
glucose (mg/dl) All 2 92 1.81 [-5.28, 8.90] 13 
 Low 
carbohydrate 
(24) 1 30 1.00 [-8.14, 10.14] 
- 
 Soya protein 
(14) 1 62 3.03 [-8.20, 14.26] 
- 
Change in HOMA-IR 
(uUI/ml x mmol/L) 
All  
4 212 -1.10 [-2.26, 0.07] 
90 
 DASH (35) 1 33 -1.90 [-2.36, -1.44] - 
 Low 
carbohydrate 
(12) 1 12 0.60 [-1.90, 3.10] 
- 
 Soya protein 
(26) 1 68 -2.00 [-3.17, -0.83] 
- 
 Behavior (23) 1 99 -0.30 [-0.71, 0.11] - 
Change in HbA1c (%) All  7 407 -0.05 [-0.13, 0.02] 84 
 Low GI (28; 29) 2 167 0.01 [-0.02, 0.03] 0 
 DASH (21) 1 34 -0.25 [-0.42, -0.08] - 
 Fat modification 
(27) 1 25 0.10 [-0.14, 0.34] 
- 
 Soya protein 
(14) 1 62 -0.01 [-0.07, 0.05] 
- 
 Behavior (23) 1 99 -0.19 [-0.26, -0.12] - 
 Ethnic diet (33) 1 20 -0.05 (-0.27, 0.17) - 
 
   
Relative Risk [95% 
CI] 
 
Medication treatment All  15 1023 0.65 [0.47, 0.88] 55 
 Low GI (13; 25; 
28; 29) 4 293 0.80 [0.55, 1.14] 
34 
 DASH (21; 22; 
35) 3 119 0.29 [0.17, 0.50] 
0 
 Low 
carbohydrate 
(30) 1 150 1.00 [0.75, 1.34] 
- 
 Energy 
restriction (31)  1 117 1.05 [0.47, 2.34] 
- 
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 Fat modification 
(34) 1 84 Not estimable 
- 
 Soya protein 
(14; 26) 2 130 0.44 [0.21, 0.91] 
0 
 Behavior (23) 1 99 0.61 [0.15, 2.42] - 
 Ethnic (33) 1 20 2.00 [0.21, 18.69] - 
 Fiber (32) 1 11 Not estimable - 
Infant Birthweight Outcomes   
    Mean [95% CI]  
Birthweight (g) All  
16 841 
-170.62 [-333.64, -
7.60] 
88 
 Low GI (13; 25; 
28; 29) 4 276 
-54.25 [-178.98, 
70.47] 
0 
 DASH (21; 22; 
35) 3 119 
-598.19 [-663.09, -
533.30] 
0 
 Low 
carbohydrate 
(12; 24) 2 42 
57.73 [-164.93, 
280.39] 
0 
 Energy 
restriction (31) 1 122 
194.00 [-42.58, 
430.58] 
- 
 Fat modification 
(27; 34) 2 109 
-139.61 [-294.80, 
15.58] 
0 
 Soya protein 
(14; 26) 2 131 
-184.67 [-319.35, -
49.98] 
0 
 
Ethnic diet (33) 1 20 
-370.00 [-928.87, 
188.87] 
- 
 
Fiber (32) 1 22 
-94.00 [-446.68, 
258.68] 
- 
  
  
Relative Risk [95% 
CI] 
 
Large for gestational age All (33) 8 647 0.96 [0.63, 1.46] 0 
 Low GI (13; 25; 
28) 3 193 1.33 [0.54, 3.31] 
0 
 Low 
carbohydrate 
(30) 1 149 0.51 [0.13, 1.95] 
- 
 Energy 
restriction (31) 1 123 1.17 [0.65, 2.12] 
- 
 Soya protein 
(14) 1 63 0.45 [0.04, 4.76] 
- 
 Behavior (23) 1 99 0.73 [0.25, 2.14] - 
 Ethnic diet (33) 1 20 0.14 [0.01, 2.45] - 
Macrosomia  All  12 834 0.49 [0.27, 0.88] 11 
 Low GI (13; 25; 
28; 29) 4 276 0.46 [0.15, 1.46] 
0 
34 
 
 DASH (22; 35) 2 85 0.12 [0.03, 0.51] 0 
 Low 
carbohydrate 
(24; 30)  2 179 0.20 [0.02, 1.69] 
- 
 Energy 
restriction (31) 1 122 1.56 [0.61, 3.94] 
- 
 Fat modification 
(34) 1 84 0.35 [0.04, 3.23] 
- 
 Soya protein 
(26) 1 68 0.60 [0.16, 2.31] 
- 
 Ethnic diet (33) 1 20 0.20 [0.01, 3.70] - 
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Table 3: Sensitivity analysis of primary maternal glycemic and infant birthweight outcomes 
 
Outcome  Diet Subgroup No. of 
Studies 
No. of 
Women 
Effect estimate I2 (%) 
Maternal Glycemic Outcomes 
    Mean [95% CI]  
Change in fasting 
glucose (mg/dl) All diets 10 575 
-1.98 [-5.41, 
1.45] 74 
 Low GI (25; 
28; 29) 3 195 
-5.33 [-6.91, -
3.76] 0 
 DASH 0 0 Not estimable - 
 Low 
carbohydrate 
(12; 24)  2 42 
3.66 [-4.42, 
11.73] 57 
 Fat 
modification 
(27; 34) 2 109 
4.88 [-1.45, 
11.21] 0 
 Soya protein 
(14; 26) 2 130 
-7.51 [-20.31, 
5.30] 90 
 
Behavior (23) 1 99 
-1.50 [-6.47, 
3.47] - 
 Ethnic  0 0 Not estimable - 
Change in 
postprandial 
glucose (mg/dl) All diets  7 421 
-5.90 [-7.93, -
3.88] 
0 
 Low GI (25; 
29) 2 121 
-7.08 [-12.07, -
2.08] 
4 
 DASH 0 0 Not estimable - 
 Low 
carbohydrate 
(24) 1 30 
-3.00 [-8.15, 
2.15] 
- 
 Fat 
modification 
(27; 34) 2 109 
-4.85 [-13.32, 
3.62] 
40 
 Soya protein 
(14) 1 62 
-1.05 [-9.73, 
7.63] 
- 
 
Behavior (23) 1 99 
-6.90 [-9.85, -
3.95] 
- 
 Ethnic 0 0 Not estimable - 
Change in post-
breakfast glucose 
(mg/dl) All diets  3 175 
-4.76 [-9.13, -
0.38] 34 
 
Low GI (29) 1 83 
-8.6 [-14.11, -
3.09]  
- 
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 Low 
carbohydrate 
(24) 1 30 
-3.00 [-8.15, 
2.15] 
- 
 Soya protein 
(14) 1 62 
-1.05 [-9.73, 
7.63] 
- 
Change in post-
lunch glucose 
(mg/dl) All diets  2 92 
4.50 [-1.90, 
10.90] 0 
 Low 
carbohydrate 
(24) 1 30 
4.00 [-4.56, 
12.56] 
- 
 Soya protein 
(14) 1 62 
5.14 [-4.51, 
14.79] 
- 
Change in post-
dinner glucose 
(mg/dl)  2 92 
1.81 [-5.28, 
8.90] 0 
 Low 
carbohydrate 
(24) 1 30 
1.00 [-8.14, 
10.14] 
- 
 Soya protein 
(14) 1 62 
3.03 [-8.20, 
14.26] 
- 
Change in HOMA-
IR 
(uUI/ml x mmol/l) 
All  
3 179 
-0.74 [-2.09, 
0.61] 
75 
 DASH 0 0 Not estimable - 
 Low 
carbohydrate 
(12)  1 12 
0.60 [-1.90, 
3.10] 
- 
 Soya protein 
(26) 1 68 
-2.00 [-3.17, -
0.83] 
- 
 
Behavior (23) 1 99 
-0.30 [-0.71, 
0.11] 
- 
Change in HbA1c 
(%) 
All 
5 353 
-0.03 [-0.11, 
0.05] 
87 
 Low GI (28; 
29) 2 167 
0.01 [-0.02, 
0.03] 
0 
 DASH 0 0 Not estimable - 
 Fat 
modification 
(27) 1 25 
0.10 [-0.14, 
0.34] 
- 
 Soya protein 
(14) 1 62 
-0.01 [-0.07, 
0.05] 
- 
 
Behavior (23) 1 99 
-0.19 [-0.26, -
0.12] 
- 
 Ethnic diet 0 0 Not estimable - 
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Relative Risk 
[95% CI] 
 
Medication 
treatment 
All 
11 884 0.82 [0.65, 1.04] 
24 
 Low GI (13; 
25; 28; 29) 4 293 0.80 [0.55, 1.14] 
34 
 DASH 0 0 Not estimable - 
 Low 
carbohydrate 
(30) 1 150 1.00 [0.75, 1.34] 
- 
 Energy 
restriction (31) 1 117 1.05 [0.47, 2.34] 
- 
 Fat 
modification 
(34) 1 84 Not estimable 
- 
 Soya protein 
(14; 26) 2 130 0.44 [0.21, 0.91] 
0 
 Behavior (23) 1 99 0.61 [0.15, 2.42] - 
 Ethnic 0 0 Not estimable - 
 Fiber (32) 1 11 Not estimable - 
Infant Birthweight Outcomes   
    Mean [95% CI]  
Birthweight (g) All 12 702 
-74.88 [-144.86, 
-4.90] 
1 
 Low GI (13; 
25; 28; 29) 4 276 
-54.25 [-178.98, 
70.47] 
0 
 DASH 0 0 Not estimable - 
 Low 
carbohydrate 
(12; 24) 2 42 
57.73 [-164.93, 
280.39] 
0 
 Energy 
restriction (31) 1 122 
194.00 [-42.58, 
430.58] 
- 
 Fat 
modification 
(27; 34) 2 109 
-139.61 [-
294.80, 15.58] 
0 
 Soya protein 
(14; 26) 2 131 
-184.67 [-
319.35, -49.98] 
0 
 Ethnic diet 0 0 Not estimable - 
 
Fiber (32) 1 22 
-94.00 [-446.68, 
258.68] 
- 
  
  
Relative Risk 
[95% CI] 
 
Large for 
gestational age 
All  
7 627 1.00 [0.66, 1.53] 
0 
 Low GI (13; 
25; 28) 3 193 1.33 [0.54, 3.31] 
0 
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 Low 
carbohydrate 
(30) 1 149 0.51 [0.13, 1.95] 
- 
 Energy 
restriction (31) 1 123 1.17 [0.65, 2.12] 
- 
 Soya protein 
(14) 1 63 0.45 [0.04, 4.76] 
- 
 Behavior (23) 1 99 0.73 [0.25, 2.14] - 
 Ethnic diet 0 0 Not estimable - 
Macrosomia  All  9 729 0.73 [0.40, 1.31] 0 
 Low GI (13; 
25; 28; 29) 4 276 0.46 [0.15, 1.46] 
0 
 DASH 0 0 Not estimable 0 
 Low 
carbohydrate 
(24; 30) 2 179 0.20 [0.02, 1.69] 
- 
 Energy 
restriction (31) 1 122 1.56 [0.61, 3.94] 
- 
 Fat 
modification 
(34) 1 84 0.35 [0.04, 3.23] 
- 
 Soya protein 
(26) 1 68 0.60 [0.16, 2.31] 
- 
 Ethnic diet 0 0 Not estimable - 
 
